Not for distribution by US newswire or in United States
NESS-ZIONA, ISRAEL – October 12, 2021 – VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company provides an update on research on the utilization of P-Esbp polymer as a novel anti-cancer drug.
As recently reported, Vaxil is making progress in the licensed drug delivery polymer that targets, with high affinity, E-selectin (P-Esbp), which was invented by Prof. Ayelet David, Head of the Drug Targeting and Nanomedicine Laboratory, Department of Clinical Biochemistry and Pharmacology from Ben-Gurion University of the Negev. E-selectin is an important component in inflammation, metastasis, and tumor growth processes, and Prof. Ayelet David’s previous work demonstrated therapeutic efficacy of P-Esbp conjugated with the anti-cancer drug doxorubicin (P-Esbp-DOX) in prolonging the survival of tumor-bearing mice with both primary (Lewis lung carcinoma) and metastatic tumors (melanoma lung metastasis model).
In order to further explore and establish the potential of P-Esbp-DOX for treating metastic cancer, an in-vivo experiment was designed aimed at evaluating the therapeutic efficacy of P-Esbp-DOX in a mouse model of aggressive liver metastasis of colorectal tumors. To this end, P-Esbp was successfully conjugated with DOX, and the maximum tolerated dose of P-Esbp-DOX was determined in the suitable mouse strain. Preliminary results of this experiment demonstrates at day 45, 70% of animals (5/7) treated with a single dose of P-Esbp-DOX-FITC at day 4 post tumor implantation remain alive and 40% (3/7) appear tumor free. This is compared to 1/6 and 0/6 animals alive in the alternate treatment and control arms.
Vaxil is completing the final report including in vivo imaging in the coming month and will share the data when complete.
Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The Company aims to continue to develop ImMucin™, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.
Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatic approach. These signal peptides induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer: The Company cautions that COVID-19 Vaccine Development is still under early-stage research and development and is not making any express or implied claims that it has the ability to eliminate the COVID-19 virus at this time. The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, the results of exploration activities — that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.
For further information please visit https://vaxil-bio.com/ or contact:
Gadi Levin, CFO — firstname.lastname@example.org, 647-558-5564